and 172.7 g (group B). Catheterization time was 1.7 days for group A and 8.5 days in group B. Hospital stay was 2.3 days in group A and 11.9 days in group B. Hemoglobin decrease was with a median value of 1.05 in group A vs 5.43 g/dL in group B. 27 group B patients (14.06%) required blood transfusion due to postoperative bleeding, this happened only in 3 patients in group A.. During the 3 months of follow-up, the procedures did not demonstrate a significant difference in Qmax, IPSS and PVR.
INTRODUCTION AND OBJECTIVES: Thulium Laser enucleation of Prostate (ThuLEP) is currently one of the alternative to open prostatectomy in patients with BHP over 80 cc. Anyway large prostate glands enucleation is believed to be more complicated (despite the learning curve) and time-consuming procedure. The aim of our study is to report intraoperative, early and long term postoperative outcomes in BPH patients larger than 150 cc.
METHODS: Our prospective study included 385 patients aged 68.2 (55-85) years with chronic and acute urinary obstruction (IPSS>20, Qmax<12) due to BPH large than 150 cc. 193 patients (Group A) underwent ThuLEP and 192 patients (Group B) underwent open prostatectomy. Patients with urethral strictures, bladder stones, acute inflammation of the genitourinary tract or a history of prior prostate surgery were excluded. Cyber TM 200 (Quanta System, Italy) was employed with subsequent Piranha morcellator (Richard Wolf, Germany) to remove prostatic lobes. All patients were evaluated preoperatively and postoperatively with regards to blood loss, catheterization time, irrigation volume, hospital stay and operative time. At 3 months after surgery they were also evaluated by International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), and postvoid residual urine volume (PVR).
RESULTS: Mean BPH volume was 196.0 cc (150-350 cc) in the ThuLEP group and 189.0 cc (150-280 cc) in the open prostatectomy group. Mean surgery time was 115.5AE44.7 min for ThuLEP and 98.5AE26.2 min for open prostatectomy. Mean mass of removed tissue was 149.0 g (group Ð) and 172.7 g (group B). Catheterization time was 1.7 days for group A and 8.5 days in group B. Hospital stay was 2.3 days in group A and 11.9 days in group B. Hemoglobin decrease was with a median value of 1.05 in group A vs 5.43 g/dL in group B. 27 group B patients (14.06%) required blood transfusion due to postoperative bleeding, this happened only in 3 patients in group A.. During the 3 months of follow-up, the procedures did not demonstrate a significant difference in Qmax, IPSS and PVR.
CONCLUSIONS: Despite similar results after three months from the procedure simple transvescical prostatectomy is characterized by longer postoperative hospitalization and catheterization time and more blood loss than ThuLEP. Even without statistical evidence Thu-LEP is a little bit longer surgical procedure but it proved to be a safer treatment option for BPH over 150 cc. METHODS: Two hundred fourteen patients were enrolled in our study who underwent HoLEP between December 2016 and August 2018. PTD is a continuous variable and dichotomized via the median split (1g/mL) procedure to form high and low groups for the comparison of the perioperative parameters. The group 1 (PTD<1 g/mL) had 100 patients and the group 2 (PTD!1 g/mL) had 114 patients. Procedures were performed in patients with LUTS and inadequate response to medical therapy, maximum urinary flow rate (Qmax) <15 ml/s, as well as gross hematuria, recurrent urinary tract infections, postvoid residual (PVR) volume >150 ml and acute urinary retention due to BPH. Patients with neurogenic bladder, confirmed prostate or bladder cancer, urethral stricture, patients using dutasterid and previous prostate surgeries were excluded. Enucleation time (ET), morcellation time (MT), total operation time (TOT), total laser energy (TLE), efficiency of laser (EL), efficiency of enucleation (EE), efficiency of morcellation (ME), enucleation rate (ER), enuclated tissue weight (ETW) were recorded.
RESULTS: The mean ages of the group 1 and group 2 were 61.36AE5.92 and 63.1AE7.52 years, respectively. TOT, ET, EE, ETW were not significant between the two groups. However, the MT was longer in group 2 with than in group 1(11.27AE8.57 min&7.22AE5.46 min, p[0.0001). Further, EM was higher in group 1 than in group 2 (9.81AE5.61g/min snf &7.45AE4.14 g/min, p[0.0003).The EL and TLE were similar in both groups (Table 1) . PTD positively correlated with MT (rho[0.272, p[0.0005) and negatively correlated with EM (rho [-0.315, p[0.0001) . No correlations were identified between the PTD and EL or EE (Figure 1-2) .
CONCLUSIONS: PTD is a factor that influences the HoLEP on perioperative outcomes. The PTD particularly affects the morcellation phase of the surgery. Patients with higher PTD will have a longer duration of MT and lesser EM. Future studies with the use of different imaging methods will give insight into the duration and difficulty of the HoLEP.
INTRODUCTION AND OBJECTIVES:
HoLEP is gaining popularity for management BPH. Long-term complications of HoLEP include urethral strictures (US) and bladder neck contracture (BNC). Studies report rates of 2.8-4.4% and 3.6-5.4% for US and BNC, respectively. To date, there are no studies that have shown the difference between resectoscope sheath size and urethral complications. Our objective is to determine the rate of US and BNC between patients who undergo HoLEP surgery with 26Fr vs. 28Fr resectoscope sheaths (RS).
METHODS: After IRB approval, a retrospective chart review of patients who had HoLEP surgery by a single surgeon between August 2015 to June 2018. Patients with prior history of US or BNC were excluded. The operative set-up for a HoLEP includes Ho:YAG laser, urethral dilation to 28 or 30Fr, use of a 26Fr or 28Fr continuous flow RS, and use of a tissue morcellator. Standard post-op care included overnight observation on continuous bladder irrigation and voiding trial on the post-op day (POD) 1 if minimal hematuria. Primary endpoints were the presence of postoperative urethral stricture or bladder neck contracture. Secondary endpoints include post-operative catheterization time, the success of voiding trial and stress urinary incontinence (SUI). Statistical analysis was performed using appropriate methods.
RESULTS: Out of 500 HoLEP patients, 162 patients had surgery with a 26Fr RS (group A), and 338 patients had surgery with 28Fr RS (group B). Two patients (A) and 12 patients ( METHODS: From Jan. 2016 to Mar. 2018, there were 126 patients underwent HoLEP in our hospital because of LUTs caused by BPH. All the procedures were performed by a single surgeon with more than 200 HoLEP experience(Prof. Xiao). Perioperative data were recorded including PSA, IPSS score, volume measured by ultrasound, operation time and estimated blood loss. The membranous urethral length (MUL) was measured on coronal magnetic resonance imaging (MRI) images of each patient and was defined as the distance from the prostatic apex to the entry of the urethra into the penile bulb. The recovery of urinary continence was recorded postoperatively, during an 8 weeks follow up.
RESULTS: The mean MUL of the 126 patients measured on preoperative MRI was 14(9e22)mm. The continent rate of 2, 4, 8 weeks postoperatively were 81.0%, 89.7%, and 96.6%, respectively. The patients were divided into two groups according to MUL measured on preoperative MRI with the cutoff 14mm. There was significant difference between group A (MUL!14mm) and group B (MUL!14mm) with respect to continent rate of 2 and 4 weeks after surgery, which were 76.7% in group A versus 85.6% in group B (P[0.036); and 87.1% in group A versus 96.3% in group B (P[0.016), respectively. Whereas the continent rate of 8 weeks after surgery were 93.5% in group A versus 100% in group B. There was no significant difference between two groups (P[0.179).
CONCLUSIONS: Short MUL, which is less than 14mm, is significantly associated with delayed recovery of urinary continence after HoLEP in terms of continent rate, especially in early stage (1 month) after the procedure.
